These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18227543)

  • 21. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
    Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies.
    Klivényi G; Schuhmacher J; Patzelt E; Hauser H; Matys R; Moock M; Regiert T; Maier-Borst W
    J Nucl Med; 1998 Oct; 39(10):1769-76. PubMed ID: 9776285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
    van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
    Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
    Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model.
    Hekman MCH; Rijpkema M; Bos DL; Oosterwijk E; Goldenberg DM; Mulders PFA; Boerman OC
    J Nucl Med; 2017 May; 58(5):706-710. PubMed ID: 28126888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretargeted gamma imaging of murine metastatic melanoma lung lesions with bispecific antibody and radiolabeled polymer drug conjugates.
    Gada KS; Patil V; Panwar R; Majewski S; Tekabe Y; Khaw BA
    Nucl Med Commun; 2011 Dec; 32(12):1231-40. PubMed ID: 22001720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer.
    Elekonawo FMK; Lütje S; Franssen GM; Bos DL; Goldenberg DM; Boerman OC; Rijpkema M
    EJNMMI Res; 2019 Sep; 9(1):86. PubMed ID: 31485790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
    Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
    Rossi EA; Chang CH; Losman MJ; Sharkey RM; Karacay H; McBride W; Cardillo TM; Hansen HJ; Qu Z; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7122s-7129s. PubMed ID: 16203811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.
    Meller B; Rave-Fränck M; Breunig C; Schirmer M; Baehre M; Nadrowitz R; Liersch T; Meller J
    Strahlenther Onkol; 2011 Feb; 187(2):120-6. PubMed ID: 21271227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies.
    Schuhmacher J; Kaul S; Klivényi G; Junkermann H; Magener A; Henze M; Doll J; Haberkorn U; Amelung F; Bastert G
    Cancer Res; 2001 May; 61(9):3712-7. PubMed ID: 11325843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
    Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
    World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.
    Bodet-Milin C; Ferrer L; Rauscher A; Masson D; Rbah-Vidal L; Faivre-Chauvet A; Cerato E; Rousseau C; Hureaux J; Couturier O; Salaün PY; Goldenberg DM; Sharkey RM; Kraeber-Bodéré F; Barbet J
    Front Med (Lausanne); 2015; 2():84. PubMed ID: 26640780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
    Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Ansquer C; Rauscher A; Frampas E; Toulgoat F; Masson D; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2021 Sep; 62(9):1221-1227. PubMed ID: 33547213
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.